Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance.
Saved in:
| Title: | Compounds activating VCP D1 ATPase enhance both autophagic and proteasomal neurotoxic protein clearance. |
|---|---|
| Authors: | Wrobel L; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Hill SM; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 413 45, Gothenburg, Sweden., Djajadikerta A; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Fernandez-Estevez M; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Karabiyik C; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Ashkenazi A; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Barratt VJ; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Stamatakou E; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom., Gunnarsson A; Biophysics SE, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Rasmusson T; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Boston, MA, USA., Miele EW; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Boston, MA, USA., Beaton N; Biognosys AG, Wagistrasse 21, 8952, Schlieren, Switzerland., Bruderer R; Biognosys AG, Wagistrasse 21, 8952, Schlieren, Switzerland., Feng Y; Biognosys AG, Wagistrasse 21, 8952, Schlieren, Switzerland., Reiter L; Biognosys AG, Wagistrasse 21, 8952, Schlieren, Switzerland., Castaldi MP; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Boston, MA, USA., Jarvis R; Discovery UK, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Tan K; Discovery UK, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Bürli RW; Discovery UK, Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rubinsztein DC; Department of Medical Genetics, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom. dcr1000@cam.ac.uk.; UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY, United Kingdom. dcr1000@cam.ac.uk. |
| Source: | Nature communications [Nat Commun] 2022 Jul 16; Vol. 13 (1), pp. 4146. Date of Electronic Publication: 2022 Jul 16. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
